Good afternoon and welcome to Markets Desk, your midday read on the stories moving markets and the broader economy.
Johnson and Johnson scored a meaningful regulatory win today as the FDA approved Imaavy, a new treatment for warm autoimmune hemolytic anemia targeting patients twelve and older. It is a rare blood disease with limited existing options, and approvals like this tend to move the needle for J and J's specialty pharma pipeline at a moment when the company needs fresh growth catalysts.
Shifting to energy, a milestone worth marking: for the first time in American history, solar generated more electricity than coal in May of two thousand twenty six. That crossover point, what analysts are calling the great solar-coal flip, reflects years of accelerating capacity buildout and signals a structural shift in how utilities plan their generation mix going forward.
And in crypto, Bitcoin is up twenty five percent in August alone, putting it on pace for its strongest August since two thousand seventeen. Whether that momentum reflects genuine institutional conviction or another liquidity-driven surge is the question traders are wrestling with. The macro backdrop, including Fed rate expectations, will likely determine whether this move has legs into September.
That's the tape. Markets Desk, signing off the floor.
